During the pre-market session on Tuesday, shares of Poseida Therapeutics, Inc. (PSTX) skyrocketed by 224.65%, fueled by the announcement of a merger agreement to be acquired by Roche Holdings, Inc. in a deal valued at up to $1.5 billion on a fully diluted basis.
Under the terms of the agreement, Roche will launch a tender offer to acquire all outstanding shares of Poseida for $9.00 per share in cash, plus a non-tradeable contingent value right (CVR) to receive up to an additional $4.00 per share in cash upon achieving specific milestones. The transaction is expected to close in the first quarter of 2025.
The acquisition aims to establish a new core capability for Roche in allogeneic cell therapy, with lead opportunities focused on the existing strategic collaboration between Poseida and Roche in hematologic malignancies. It will also include Poseida's CAR-T programs for solid tumors and autoimmune diseases, its genetic engineering platform, and related preclinical medicines.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.